FAQ on Quantum BioPharma Ltd.'s Support for Unbuzzd's $5 Million Regulation D Offering
Summary
What is the main purpose of Unbuzzd’s $5 million raise?
The funds raised by Unbuzzd Wellness Inc. through the Regulation D 506(c) offering are intended to expand its direct-to-consumer, retail, and distributor reach for its product unbuzzd(TM), a beverage designed to speed alcohol metabolism and reduce hangover symptoms.
Who is leading Unbuzzd Wellness Inc.?
Unbuzzd Wellness Inc. is led by CEO John Duffy, a former Coca-Cola executive, and is advised by Gerry David, the ex-CEO of Celsius Holdings.
What is Quantum BioPharma Ltd.’s relationship with Unbuzzd?
Quantum BioPharma Ltd. is a biopharmaceutical company that retains a 25.71% ownership in Celly Nutrition Corp., the company behind Unbuzzd, as of June 30, 2024, and receives royalty payments from sales of unbuzzd(TM).
What are the terms of the royalty payments Quantum BioPharma receives from Unbuzzd?
Quantum BioPharma receives royalty payments of 7% of sales from unbuzzd(TM) until payments total $250 million, after which the royalty drops to 3% in perpetuity.
What is Quantum BioPharma Ltd.’s focus in the biopharmaceutical sector?
Quantum BioPharma Ltd. is dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders, with drug candidates in various stages of development.
Where can investors find the latest news and updates about Quantum BioPharma Ltd.?
The latest news and updates relating to Quantum BioPharma Ltd. (QNTM) are available in the company’s newsroom at https://ibn.fm/QNTM.
What is the significance of the Regulation D 506(c) offering for Unbuzzd?
The Regulation D 506(c) offering allows Unbuzzd to raise up to $5 million from accredited investors without the need for a public offering, facilitating its expansion and moving closer to a potential future IPO.
What rights does Quantum BioPharma retain regarding Unbuzzd’s products?
Quantum BioPharma retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses, separate from the OTC version spun out to Celly Nutrition Corp.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 99620